A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe - Trial NCT06402513
Access comprehensive clinical trial information for NCT06402513 through Pure Global AI's free database. This Phase 1 trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AbbVie
Timeline & Enrollment
Phase 1
Jun 24, 2024
Oct 09, 2024
Primary Outcome
Maximum Observed Plasma Concentration (Cmax),Time to Maximum Observed Plasma Concentration (Tmax),Apparent Terminal Phase Elimination Rate Constant (ฮฒ),The Terminal Phase Elimination Half-Life (t1/2),The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt),The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCโ),Number of Anti-drug antibody (ADA) Titers,Number of Participants with Adverse Events
Summary
The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and
 tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy
 adult participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06402513
Non-Device Trial